Cover Image

AGO algorithms for the treatment of breast cancer: update 2021 = AGO-Algorithmen zur Behandlung von Brustkrebs : Update 2021

Therapy options shown in the algorithms are based on the current AGO recommendations, but cannot represent all evidence-based treatment options, since prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. In individua...

Full description

Saved in:
Bibliographic Details
Main Authors: Schneeweiss, Andreas (Author) , Fasching, Peter A. (Author) , Fehm, Tanja (Author) , Gerber, Bernd (Author) , Jackisch, Christian (Author) , Loibl, Sibylle (Author) , Schmidt, Marcus (Author) , Stickeler, Elmar (Author) , Wöckel, Achim (Author) , Janni, Wolfgang (Author) , Müller, Volkmar (Author)
Format: Article (Journal)
Language:English
Published: 06 October 2021
In: Geburtshilfe und Frauenheilkunde
Year: 2021, Volume: 81, Issue: 10, Pages: 1101-1111
ISSN:1438-8804
DOI:10.1055/a-1519-7089
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1519-7089
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1519-7089
Get full text
Author Notes:Andreas Schneeweiss, Peter A. Fasching, Tanja Fehm, Bernd Gerber, Christian Jackisch, Sibylle Loibl, Marcus Schmidt, Elmar Stickeler, Achim Wöckel, Wolfgang Janni, Volkmar Müller, on behalf of the AGO Kommission Mamma
Description
Summary:Therapy options shown in the algorithms are based on the current AGO recommendations, but cannot represent all evidence-based treatment options, since prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. In individual cases, other evidence-based treatment options may also be appropriate and justified. Regardless of approval status, the algorithms only take into account drugs that were available in Germany at the time the algorithm was last updated. Here we present the 2021 update of AGO treatment algorithms for early and metastatic breast cancer, which are intended to intensify structured treatment decision by providing reproducible and evidence-based treatment paths and may be helpful for a broad treatment landscape.
Item Description:Gesehen am 29.01.2022
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-1519-7089

Similar Items